36895570 35640925 36477638 36444724 36581047 36059541 37112761 35396461 36250571 35746512 35459237 35613223 36301977 36524941 35366961 37041143 36048716 36438045 37097556 35545351 35588753 35608504 35979361 36519113 37182520 35813281 36780914 3645473 - Search Results

Year	Number of Results
2022	35
2023	21

1

Complementarity determining regions in SARS-CoV-2 hybrid immunity.

Frans G, Dillaerts D, Dehaemers T, Van Elslande J, De Leeuw J, Boon L, Maes W, Callewaert N, Calcoen B, Ancheva L, Cockx M, Geukens N, Arat K, Derua R, Vermeersch P, Carpentier SC, Bossuyt X. Frans G, et al. Front Immunol. 2023 Feb 21;14:1050037. doi: 10.3389/fimmu.2023.1050037. eCollection 2023. Front Immunol. 2023. PMID: 36895570 Free PMC article.

2

Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis.

Au WY, Cheung PP. Au WY, et al. BMJ. 2022 May 31;377:e069989. doi: 10.1136/bmj-2022-069989. BMJ. 2022. PMID: 35640925 Free PMC article.

3

Development of therapeutic vaccines for the treatment of diseases.

Tian Y, Hu D, Li Y, Yang L. Tian Y, et al. Mol Biomed. 2022 Dec 8;3(1):40. doi: 10.1186/s43556-022-00098-9. Mol Biomed. 2022. PMID: 36477638 Free PMC article. Review.

4

Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination.

Wang M, Zhou B, Fan Q, Zhou X, Liao X, Lin J, Ma Z, Dong J, Wang H, Ge X, Ju B, Zhang Z. Wang M, et al. Emerg Microbes Infect. 2023 Dec;12(1):2151381. doi: 10.1080/22221751.2022.2151381. Emerg Microbes Infect. 2023. PMID: 36444724 Free PMC article.

5

Targeting SARS-CoV-2 and host cell receptor interactions.

Lim SP. Lim SP. Antiviral Res. 2023 Feb;210:105514. doi: 10.1016/j.antiviral.2022.105514. Epub 2022 Dec 26. Antiviral Res. 2023. PMID: 36581047 Free PMC article. Review.

6

Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission.

Russell MW, Mestecky J. Russell MW, et al. Front Immunol. 2022 Aug 17;13:957107. doi: 10.3389/fimmu.2022.957107. eCollection 2022. Front Immunol. 2022. PMID: 36059541 Free PMC article. Review.

7

SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines.

Sunagar R, Singh A, Kumar S. Sunagar R, et al. Vaccines (Basel). 2023 Apr 15;11(4):849. doi: 10.3390/vaccines11040849. Vaccines (Basel). 2023. PMID: 37112761 Free PMC article. Review.

8

Do individuals who have recovered from COVID-19 still benefit from being vaccinated?

Flemming A. Flemming A. Nat Rev Immunol. 2022 May;22(5):275. doi: 10.1038/s41577-022-00724-1. Nat Rev Immunol. 2022. PMID: 35396461 Free PMC article. No abstract available.

9

Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study.

Wan EYF, Mok AHY, Yan VKC, Chan CIY, Wang B, Lai FTT, Chui CSL, Li X, Wong CKH, Lau CS, Wong ICK, Chan EWY. Wan EYF, et al. J Travel Med. 2022 Dec 27;29(8):taac119. doi: 10.1093/jtm/taac119. J Travel Med. 2022. PMID: 36250571 Free PMC article.

10

Understanding COVID-19 Vaccines Today: Are T-cells Key Players?

Shafqat A, Arabi TZ, Sabbah BN, Abdulkader HS, Shafqat S, Razak A, Kashir J, Alkattan K, Yaqinuddin A. Shafqat A, et al. Vaccines (Basel). 2022 Jun 6;10(6):904. doi: 10.3390/vaccines10060904. Vaccines (Basel). 2022. PMID: 35746512 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

51 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year